SlideShare ist ein Scribd-Unternehmen logo
1 von 15
Downloaden Sie, um offline zu lesen
Vioxx Decisions-Were they ethical? Randal williamsamrohussien
The history of Merck The roots date back to 1827 with Heinrich Emanuel Merck as the founder who began an industrial-scale production of Alkaloids, plant extracts, and other chemicals The successful export business in the United States led in 1887 to the establishment of a subsidiary in New York. Under George Merck, a grandson of Heinrich Emmanuel Merck, Merck & Co, was formed in 1891
History of Merck (cont) Merck and Co. became an independent company in the United States after World War I The two companies are no longer linked today but the one thing that they have in common is the name Merck Merck & Co. holds the rights to the name in North America and outside this region the U.S Company operates as Merck Sharp and Dohme (MSD) or MSD Sharp & Dohme
What is Vioxx? Vioxx is a nonsteroidal anti- inflammatory drug( NSAID) that exhibits anti-inflamitory , analgesic, and antipyretic activities NSAIDs are a large class of medications used to treat arthritis pain and inflammation There are three categories of NSAIDs: Salicylates such as aspirin, the traditional NSAIDs, and the COX-2 selective inhibitors
Vioxx (cont) The FDA approved Vioxx in May 1999 for the reduction of signs and symptoms of osteoarthritis, as well as for acute pain in adults Vioxx has demonstrated significant reduction in joint pain compared to placebo
VIGOR study After Vioxx was approved in 1999, Merck created a VIGOR (VIOXX Gastro Intestinal Outcomes Research) which was designed to look into GI effects which included stomach ulcers and bleeding VIGOR was a randomized, double-blinded study in 8,076 patients with rheumatoid arthritis requiring chronic NSAID. The patients were not allowed to use concomitant aspirin or other anti-platelet drugs.
VIGOR (cont) The study concluded that there was an increase of serious cardiovascular events including heart attacks and strokes, in patients taking Vioxx compared to patients taking naproxen
Lawsuits against Vioxx The first VIOXX lawsuit, was a wrongful death case heard in a Texas courtroom.  The jury decided by 10-2 vote on August 19, 2005, that Merck was liable and awarded $253.4 million to the widow of Robert Ernst Under Texas law the amount is expected to be reduced to $26.1 million
Lawsuits (cont) Merck eventually settled the lawsuits out of court for $4.85 billion this agreement settled 27,000 lawsuits for 47,000 plaintiffs The legal defense for Merck cost them $1.2 billion The average plaintiff will receive just over $100,000 before fees and expenses, which usually run between 30-50% The plaintiff’s attorneys will receive almost $2 billion in fees
Lawsuits (cont) Merck has also had to settle with unions and insurers for $80 million Shareholders of Merck filed suit against the officers of Merck on behalf of the company and came to an agreement that the officers would pay $12.5 million in legal fees
Lawsuits by the shareholders There is a case pending between Merck and its shareholders, on April 27th of this year, the Supreme Court ruled that the lawsuit could proceed Merck stated that under the Sarbanes-Oxley act of 2002, that the statue of limitations had run out on the lawsuit.  Section 804 of the Sarbanes-Oxley act states that in regarding fraud, a lawsuit can be brought within the first two years that the fraud is uncovered Merck claims that more than two years prior to the filing the plaintiffs had or could have discovered the “facts constituting the violation, and therefore was barred by the applicable statute of limitations”
Problems around the world Currently there are lawsuits pending and being decided in Australia against Merck On March 5th of 2010 the Australian federal court ruled in favor of the Plaintiff (Peterson) and awarded him a settlement of $287,000 Australian dollars The judge found that Merck failed to warn his Doctor of the cardiovascular risk associated with Vioxx, the judge cited the VIRGO study and said that Merck had violated Australian trade practices
What the %$#@? Dr. Scott S. Reuben was a Doctor performing studies for Merck and other pharmaceutical companies Reuben has now admitted that he never conducted any of the clinical trials on which his conclusions were based  Scientific American has called Reuben the medical equivalent of Bernie Madoff Reuben was sentenced in Federal Court to six months in jail (after pleading guilty to one count of health care fraud on February 21, 2010) to be followed by three years of supervised release.  Further, a five-thousand dollar fine was imposed and he was ordered to provide restitution of more then three hundred sixty thousand dollars.
Question 1 Utilizing the information provided and available from web sources, use the ethical decision making techniques discussed in the chapter to form an opinion about whether Merck’s decisions regarding Vioxx were ethical? Show your analysis
Question 2	 In order to protect the public more fully, what should the FDA do given the Vioxx lessons?

Weitere ähnliche Inhalte

Was ist angesagt?

Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyDivjyot Kaur
 
Literature monitoring for pv what are we doing at galderma elsevier webinar
Literature monitoring for pv   what are we doing at galderma elsevier webinarLiterature monitoring for pv   what are we doing at galderma elsevier webinar
Literature monitoring for pv what are we doing at galderma elsevier webinarAnn-Marie Roche
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiologylateef khan
 
Importance of aggregate reporting in pharmacovigilance
Importance of aggregate reporting in pharmacovigilanceImportance of aggregate reporting in pharmacovigilance
Importance of aggregate reporting in pharmacovigilanceSollers College
 
Clinical trials dhruva
Clinical trials dhruvaClinical trials dhruva
Clinical trials dhruvaDhruva Sharma
 
The Evolution of the Clinical Trials Process – A Brief History Lesson
The Evolution of the Clinical Trials Process – A Brief History LessonThe Evolution of the Clinical Trials Process – A Brief History Lesson
The Evolution of the Clinical Trials Process – A Brief History LessonPradeep H
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsSatish Veerla
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuAngelinabarfield
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registrybiinoida
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Jobin Kunjumon Vilapurathuu
 
The Thalidomide tragedy.pptx
The Thalidomide tragedy.pptxThe Thalidomide tragedy.pptx
The Thalidomide tragedy.pptxkajal pradhan
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillanceGaurav Sharma
 

Was ist angesagt? (20)

Phase 1 clinical trial
Phase 1 clinical trialPhase 1 clinical trial
Phase 1 clinical trial
 
ECOPHARMACOVIGILANCE
ECOPHARMACOVIGILANCEECOPHARMACOVIGILANCE
ECOPHARMACOVIGILANCE
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Literature monitoring for pv what are we doing at galderma elsevier webinar
Literature monitoring for pv   what are we doing at galderma elsevier webinarLiterature monitoring for pv   what are we doing at galderma elsevier webinar
Literature monitoring for pv what are we doing at galderma elsevier webinar
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Importance of aggregate reporting in pharmacovigilance
Importance of aggregate reporting in pharmacovigilanceImportance of aggregate reporting in pharmacovigilance
Importance of aggregate reporting in pharmacovigilance
 
Clinical trials dhruva
Clinical trials dhruvaClinical trials dhruva
Clinical trials dhruva
 
The Evolution of the Clinical Trials Process – A Brief History Lesson
The Evolution of the Clinical Trials Process – A Brief History LessonThe Evolution of the Clinical Trials Process – A Brief History Lesson
The Evolution of the Clinical Trials Process – A Brief History Lesson
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And Eu
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registry
 
Off label use
Off label useOff label use
Off label use
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trials
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........
 
The Thalidomide tragedy.pptx
The Thalidomide tragedy.pptxThe Thalidomide tragedy.pptx
The Thalidomide tragedy.pptx
 
Study of Vaccine safety
Study of Vaccine safetyStudy of Vaccine safety
Study of Vaccine safety
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 
Introduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical TrialsIntroduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical Trials
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Off label use of antibiotics in pediatrics
Off label use of antibiotics in pediatricsOff label use of antibiotics in pediatrics
Off label use of antibiotics in pediatrics
 

Andere mochten auch

Vioxx case study
Vioxx case studyVioxx case study
Vioxx case studyaghussien
 
Crisis Communication Case Study -- Vioxx
Crisis Communication Case Study -- VioxxCrisis Communication Case Study -- Vioxx
Crisis Communication Case Study -- VioxxDaliaHamzeh
 
Vioxx Clinical Studies
Vioxx Clinical StudiesVioxx Clinical Studies
Vioxx Clinical StudiesAnapol Weiss
 
Merck presentation.
Merck presentation.Merck presentation.
Merck presentation.Bakryk
 
Vioxx Litigation Strategy
Vioxx Litigation StrategyVioxx Litigation Strategy
Vioxx Litigation StrategyAnapol Weiss
 
Merck and company interview questions and answers
Merck and company interview questions and answersMerck and company interview questions and answers
Merck and company interview questions and answersKateWinslet88
 
Merck group 7 strategic_mgmt
Merck group 7 strategic_mgmtMerck group 7 strategic_mgmt
Merck group 7 strategic_mgmtkirtishankar075
 
Biotecnologia industrial vol 1
Biotecnologia industrial   vol 1Biotecnologia industrial   vol 1
Biotecnologia industrial vol 1Stela Koloda
 
Fifa presentation
Fifa presentationFifa presentation
Fifa presentationPersian1
 
Merck & Co Presentation
Merck & Co PresentationMerck & Co Presentation
Merck & Co Presentationtylerrives
 
2013 10 cu leeds school big data conference - bill jacobs - revolution analytics
2013 10 cu leeds school big data conference - bill jacobs - revolution analytics2013 10 cu leeds school big data conference - bill jacobs - revolution analytics
2013 10 cu leeds school big data conference - bill jacobs - revolution analyticsBill Jacobs
 

Andere mochten auch (18)

Vioxx case study
Vioxx case studyVioxx case study
Vioxx case study
 
Case study on merck
Case study on merckCase study on merck
Case study on merck
 
Crisis Communication Case Study -- Vioxx
Crisis Communication Case Study -- VioxxCrisis Communication Case Study -- Vioxx
Crisis Communication Case Study -- Vioxx
 
merck and co. inc
merck and co. incmerck and co. inc
merck and co. inc
 
Vioxx Clinical Studies
Vioxx Clinical StudiesVioxx Clinical Studies
Vioxx Clinical Studies
 
Merck & co
Merck & coMerck & co
Merck & co
 
Merck- River Blindness
Merck- River BlindnessMerck- River Blindness
Merck- River Blindness
 
Merck presentation.
Merck presentation.Merck presentation.
Merck presentation.
 
Vioxx Litigation Strategy
Vioxx Litigation StrategyVioxx Litigation Strategy
Vioxx Litigation Strategy
 
Merck and company interview questions and answers
Merck and company interview questions and answersMerck and company interview questions and answers
Merck and company interview questions and answers
 
Merck group 7 strategic_mgmt
Merck group 7 strategic_mgmtMerck group 7 strategic_mgmt
Merck group 7 strategic_mgmt
 
Biotecnologia industrial vol 1
Biotecnologia industrial   vol 1Biotecnologia industrial   vol 1
Biotecnologia industrial vol 1
 
Fifa presentation
Fifa presentationFifa presentation
Fifa presentation
 
Fifa power point
Fifa power pointFifa power point
Fifa power point
 
Corruption
CorruptionCorruption
Corruption
 
Merck & Co Presentation
Merck & Co PresentationMerck & Co Presentation
Merck & Co Presentation
 
2013 10 cu leeds school big data conference - bill jacobs - revolution analytics
2013 10 cu leeds school big data conference - bill jacobs - revolution analytics2013 10 cu leeds school big data conference - bill jacobs - revolution analytics
2013 10 cu leeds school big data conference - bill jacobs - revolution analytics
 
Business ethics
Business ethicsBusiness ethics
Business ethics
 

Ähnlich wie Vioxx project power point presentation

WV Association for Justice Seminar SB 411
WV Association for Justice Seminar SB 411WV Association for Justice Seminar SB 411
WV Association for Justice Seminar SB 411William K. Schwartz
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaUntil ROI
 
AZT: How an abandoned drug found new life as an important AIDS/HIV treatment
AZT:  How an abandoned drug found new life as an important AIDS/HIV treatmentAZT:  How an abandoned drug found new life as an important AIDS/HIV treatment
AZT: How an abandoned drug found new life as an important AIDS/HIV treatmentFirhan Malik
 
73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docxalinainglis
 
Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)rr0006
 
Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)rr0006
 
Multiple Chemical Sensitivities Under Siege
Multiple Chemical Sensitivities Under Siege Multiple Chemical Sensitivities Under Siege
Multiple Chemical Sensitivities Under Siege v2zq
 
Kees de joncheere - Selling Sickness 2010
Kees de joncheere - Selling Sickness 2010Kees de joncheere - Selling Sickness 2010
Kees de joncheere - Selling Sickness 2010Gezonde scepsis
 
Chapter 1 pharmacy and health care
Chapter 1 pharmacy and health careChapter 1 pharmacy and health care
Chapter 1 pharmacy and health careAnn Bentley
 
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...Salvo Fedele
 
Lecture16 F&A2011
Lecture16 F&A2011Lecture16 F&A2011
Lecture16 F&A2011Ray Arons
 
Talcum Powder: Embroiled in Multi-Million Lawsuits
Talcum Powder: Embroiled in Multi-Million Lawsuits Talcum Powder: Embroiled in Multi-Million Lawsuits
Talcum Powder: Embroiled in Multi-Million Lawsuits Neural IT
 
Bextra_Under_the_skin_of_politically_driven_decision
Bextra_Under_the_skin_of_politically_driven_decisionBextra_Under_the_skin_of_politically_driven_decision
Bextra_Under_the_skin_of_politically_driven_decisionAviel Shatz
 
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docx
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docxCASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docx
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docxwendolynhalbert
 
Mensing Reglan/Generics opinion
Mensing Reglan/Generics opinionMensing Reglan/Generics opinion
Mensing Reglan/Generics opinionmzamoralaw
 
Zubulake Who?
Zubulake Who?Zubulake Who?
Zubulake Who?creddy
 

Ähnlich wie Vioxx project power point presentation (20)

MedMal news
MedMal newsMedMal news
MedMal news
 
October Newsletter
October NewsletterOctober Newsletter
October Newsletter
 
WV Association for Justice Seminar SB 411
WV Association for Justice Seminar SB 411WV Association for Justice Seminar SB 411
WV Association for Justice Seminar SB 411
 
Chapter 1
Chapter 1Chapter 1
Chapter 1
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, Cipla
 
AZT: How an abandoned drug found new life as an important AIDS/HIV treatment
AZT:  How an abandoned drug found new life as an important AIDS/HIV treatmentAZT:  How an abandoned drug found new life as an important AIDS/HIV treatment
AZT: How an abandoned drug found new life as an important AIDS/HIV treatment
 
73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx
 
Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)
 
Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)Chapter 1 pharmacy and health care(2)
Chapter 1 pharmacy and health care(2)
 
Multiple Chemical Sensitivities Under Siege
Multiple Chemical Sensitivities Under Siege Multiple Chemical Sensitivities Under Siege
Multiple Chemical Sensitivities Under Siege
 
Kees de joncheere - Selling Sickness 2010
Kees de joncheere - Selling Sickness 2010Kees de joncheere - Selling Sickness 2010
Kees de joncheere - Selling Sickness 2010
 
Anda Preemption
Anda PreemptionAnda Preemption
Anda Preemption
 
Chapter 1 pharmacy and health care
Chapter 1 pharmacy and health careChapter 1 pharmacy and health care
Chapter 1 pharmacy and health care
 
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
 
Lecture16 F&A2011
Lecture16 F&A2011Lecture16 F&A2011
Lecture16 F&A2011
 
Talcum Powder: Embroiled in Multi-Million Lawsuits
Talcum Powder: Embroiled in Multi-Million Lawsuits Talcum Powder: Embroiled in Multi-Million Lawsuits
Talcum Powder: Embroiled in Multi-Million Lawsuits
 
Bextra_Under_the_skin_of_politically_driven_decision
Bextra_Under_the_skin_of_politically_driven_decisionBextra_Under_the_skin_of_politically_driven_decision
Bextra_Under_the_skin_of_politically_driven_decision
 
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docx
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docxCASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docx
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docx
 
Mensing Reglan/Generics opinion
Mensing Reglan/Generics opinionMensing Reglan/Generics opinion
Mensing Reglan/Generics opinion
 
Zubulake Who?
Zubulake Who?Zubulake Who?
Zubulake Who?
 

Mehr von aghussien

Sas institute project presentation
Sas institute   project presentationSas institute   project presentation
Sas institute project presentationaghussien
 
The final draft for submission
The final draft for submissionThe final draft for submission
The final draft for submissionaghussien
 
Hussien amro 800326388_resume
Hussien amro 800326388_resumeHussien amro 800326388_resume
Hussien amro 800326388_resumeaghussien
 
Hussien amro 800326388_resume
Hussien amro 800326388_resumeHussien amro 800326388_resume
Hussien amro 800326388_resumeaghussien
 
Sas analysis report
Sas analysis reportSas analysis report
Sas analysis reportaghussien
 
Case Analysis PowerPoint Presentation
Case Analysis PowerPoint PresentationCase Analysis PowerPoint Presentation
Case Analysis PowerPoint Presentationaghussien
 

Mehr von aghussien (10)

Sas institute project presentation
Sas institute   project presentationSas institute   project presentation
Sas institute project presentation
 
The final draft for submission
The final draft for submissionThe final draft for submission
The final draft for submission
 
Hussien amro 800326388_resume
Hussien amro 800326388_resumeHussien amro 800326388_resume
Hussien amro 800326388_resume
 
Hussien amro 800326388_resume
Hussien amro 800326388_resumeHussien amro 800326388_resume
Hussien amro 800326388_resume
 
Cover final
Cover finalCover final
Cover final
 
Cover final
Cover finalCover final
Cover final
 
Sas analysis report
Sas analysis reportSas analysis report
Sas analysis report
 
Cover final
Cover finalCover final
Cover final
 
Cover final
Cover finalCover final
Cover final
 
Case Analysis PowerPoint Presentation
Case Analysis PowerPoint PresentationCase Analysis PowerPoint Presentation
Case Analysis PowerPoint Presentation
 

Vioxx project power point presentation

  • 1. Vioxx Decisions-Were they ethical? Randal williamsamrohussien
  • 2. The history of Merck The roots date back to 1827 with Heinrich Emanuel Merck as the founder who began an industrial-scale production of Alkaloids, plant extracts, and other chemicals The successful export business in the United States led in 1887 to the establishment of a subsidiary in New York. Under George Merck, a grandson of Heinrich Emmanuel Merck, Merck & Co, was formed in 1891
  • 3. History of Merck (cont) Merck and Co. became an independent company in the United States after World War I The two companies are no longer linked today but the one thing that they have in common is the name Merck Merck & Co. holds the rights to the name in North America and outside this region the U.S Company operates as Merck Sharp and Dohme (MSD) or MSD Sharp & Dohme
  • 4. What is Vioxx? Vioxx is a nonsteroidal anti- inflammatory drug( NSAID) that exhibits anti-inflamitory , analgesic, and antipyretic activities NSAIDs are a large class of medications used to treat arthritis pain and inflammation There are three categories of NSAIDs: Salicylates such as aspirin, the traditional NSAIDs, and the COX-2 selective inhibitors
  • 5. Vioxx (cont) The FDA approved Vioxx in May 1999 for the reduction of signs and symptoms of osteoarthritis, as well as for acute pain in adults Vioxx has demonstrated significant reduction in joint pain compared to placebo
  • 6. VIGOR study After Vioxx was approved in 1999, Merck created a VIGOR (VIOXX Gastro Intestinal Outcomes Research) which was designed to look into GI effects which included stomach ulcers and bleeding VIGOR was a randomized, double-blinded study in 8,076 patients with rheumatoid arthritis requiring chronic NSAID. The patients were not allowed to use concomitant aspirin or other anti-platelet drugs.
  • 7. VIGOR (cont) The study concluded that there was an increase of serious cardiovascular events including heart attacks and strokes, in patients taking Vioxx compared to patients taking naproxen
  • 8. Lawsuits against Vioxx The first VIOXX lawsuit, was a wrongful death case heard in a Texas courtroom. The jury decided by 10-2 vote on August 19, 2005, that Merck was liable and awarded $253.4 million to the widow of Robert Ernst Under Texas law the amount is expected to be reduced to $26.1 million
  • 9. Lawsuits (cont) Merck eventually settled the lawsuits out of court for $4.85 billion this agreement settled 27,000 lawsuits for 47,000 plaintiffs The legal defense for Merck cost them $1.2 billion The average plaintiff will receive just over $100,000 before fees and expenses, which usually run between 30-50% The plaintiff’s attorneys will receive almost $2 billion in fees
  • 10. Lawsuits (cont) Merck has also had to settle with unions and insurers for $80 million Shareholders of Merck filed suit against the officers of Merck on behalf of the company and came to an agreement that the officers would pay $12.5 million in legal fees
  • 11. Lawsuits by the shareholders There is a case pending between Merck and its shareholders, on April 27th of this year, the Supreme Court ruled that the lawsuit could proceed Merck stated that under the Sarbanes-Oxley act of 2002, that the statue of limitations had run out on the lawsuit. Section 804 of the Sarbanes-Oxley act states that in regarding fraud, a lawsuit can be brought within the first two years that the fraud is uncovered Merck claims that more than two years prior to the filing the plaintiffs had or could have discovered the “facts constituting the violation, and therefore was barred by the applicable statute of limitations”
  • 12. Problems around the world Currently there are lawsuits pending and being decided in Australia against Merck On March 5th of 2010 the Australian federal court ruled in favor of the Plaintiff (Peterson) and awarded him a settlement of $287,000 Australian dollars The judge found that Merck failed to warn his Doctor of the cardiovascular risk associated with Vioxx, the judge cited the VIRGO study and said that Merck had violated Australian trade practices
  • 13. What the %$#@? Dr. Scott S. Reuben was a Doctor performing studies for Merck and other pharmaceutical companies Reuben has now admitted that he never conducted any of the clinical trials on which his conclusions were based Scientific American has called Reuben the medical equivalent of Bernie Madoff Reuben was sentenced in Federal Court to six months in jail (after pleading guilty to one count of health care fraud on February 21, 2010) to be followed by three years of supervised release. Further, a five-thousand dollar fine was imposed and he was ordered to provide restitution of more then three hundred sixty thousand dollars.
  • 14. Question 1 Utilizing the information provided and available from web sources, use the ethical decision making techniques discussed in the chapter to form an opinion about whether Merck’s decisions regarding Vioxx were ethical? Show your analysis
  • 15. Question 2 In order to protect the public more fully, what should the FDA do given the Vioxx lessons?